The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



PROJECT SUMMARYThe Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2)-driven coronavirus disease 2019(COVID-19) pandemic has fundamentally changed our world, country, community and families. In patients whodie of COVID-19, activation of evolutionarily-conserved inflammatory cascades results in massive increases incirculating levels of inflammatory cytokines producing vascular leak, edema of multiple critical organ (lung,kidneys, heart, brain, liver, GI tract), ultimately leading to multi-organ dysfunction including acute respiratorydistress syndrome (ARDS). There is lack of deep understanding regarding the risk factors for and biology ofCOVID-19. The pandemic has also dramatically highlighted the multiple unmet needs in the care for patientswith SARS-CoV-2 infection including the lack of validated biomarkers, and of effective FDA-approvedpharmacotherapies. Accordingly, this Administrative Supplement seeks to further our understanding throughimmunophenotyping patients who develop COVID-19. We will provide clinical data and samplecollection/processing from a cohort of SARS-CoV2 patients enrolled in Tucson, Arizona. The clinical data andsamples will be transmitted to the central cores that are assigned by the Immunophenotyping Assessment in aCOVID-19 Cohort (IMPACC) study with the overarching objectives to better understand the pathogenesisof COVID-19 disease and to identify immunological pathways that can be used to inform us on how tocombat this disease. In Specific Aim 1, we will recruit and provide clinical data (demographics, clinicallaboratory test results and imaging results, clinical course) longitudinally from patients hospitalized with COVID-19 infection to the designated IMPACC cores in order to establish correlation with immune status and diseaseprogression. In Specific Aim 2, we will provide biological specimens (serum, whole blood, PBMCs,nasopharyngeal samples, endotracheal aspirates) from patients hospitalized with COVID-19 infection to thedesignated cores in order to characterize the immunophenotypes and the immune status and response toinfection. This supplement supports the University of Arizona's participation in IMPACC to facilitate screeningand enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parentU19 grant entitled "Dysfunction of Innate Immunity in Asthma" (1U19AI125357). In summary, the IMPACC studycoordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples fromhospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkersassociated with clinical disease course. These data will allow the prioritization of clinical interventions andtherapeutic decision making.